Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 362

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Open access
Janjigian, Yelena Y, Maron, Steven B, Chatila, Walid K, Millang, Brittanie, Chavan, Shweta S, Alterman, Carly, Chou, Joanne F, Segal, Michal F, Simmons, Marc Z, Momtaz, Parisa, Shcherba, Marina, Ku, Geoffrey Y, Zervoudakis, Alice, Won, Elizabeth S, Kelsen, David P, Ilson, David H, Nagy, Rebecca J, Lanman, Richard B, Ptashkin, Ryan N, Donoghue, Mark T A, Capanu, Marinela, Taylor, Barry S, Solit, David B, Schultz, Nikolaus, Hechtman, Jaclyn F·2020·The Lancet Oncology

Abstract

Summary Background Adding trastuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastatic gastric cancer. We assessed the safety and efficacy of pembrolizumab in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic esophagogastric (EG) cancer. Methods This was an open-label, non-randomized, single-arm, investigator-initiated single center phase 2 trial in patients aged 18 years or older with HER2-positive mEG cancer. Eligible patients had measurable or evaluable non-measurable disease at baseline, Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and baseline left ventricular ejection fraction of ≥ 53%. Patients were eligible to receive an initial induction cycle of intravenous (IV) pembrolizumab (200 mg flat dose) and IV trastuzumab 8 mg/kg loading dose. For subsequent cycles, patients received IV oxaliplatin 130 mg/m2 or cisplatin 80 mg/m2 on day 1, oral capecitabine 850 mg/m2 twice a day for 2 weeks followed by 1 week off, or IV 5-FU 800 mg/m2/day on day 1 to 5, and IV pembrolizumab 200 mg flat dose and trastuzumab 6 mg/kg, both administered on day 1 of each 3-week cycle. The primary endpoint was 6-month progression-free survival (PFS). Pre-treatment tumor and plasma samples were collected for confirmation of HER2 status and exploratory biomarker analysis by targeted and whole exome sequencing. This trial is registered with Clinicaltrials.gov, number NCT02954536 (ongoing, closed to enrollment). Findings Between Nov 11, 2016, and Jan 23, 2019, 37 patients were enrolled. At the time of data cutoff on Aug 6, 2019, the median follow-up among survivors was 13 months (range 6–31). The primary endpoint was achieved; 26 of 37 (70%, 95% CI 54–83%) patients were progression-free at 6 months. The overall response rate among 35 patients with measurable disease was 91% (32 patients, 95% CI 78–97%), including 6 (17%) complete responses, 26 (74%) partial responses, and 3 (8%) stable disease. The median PFS was 13.0 months (95% CI 8.6–NA), median overall survival (OS) was 27.2 months (95% CI 18.8–NA), and the 12-month OS rate was 80% (95% CI 68–95%). The most common treatment-related adverse event of any grade was neuropathy, which affected 36 (97%) of the 37 patients. Treatment-related grade 3 or 4 adverse events occurred in 21 (67%) patients, and serious adverse events occurred in 2. Two patients discontinued treatment due to treatment-related adverse events, and 4 discontinued pembrolizumab due to immune-related adverse events. ERBB2 amplification or focal gain was detected in 21 of 32 patients (66%) patients who had tumor sequencing and in 18 of 33 patients (54%) whose circulating tumor DNA (ctDNA) was sequenced. Tissue and ctDNA sequencing were concordant for presence or absence of ERBB2 amplification in 27 of 29 patients (93%). A decline in tumor-matched ctDNA was observed after the first dose of pembrolizumab and trastuzumab in 13 of the 16 patients with tumor-matched pre-treatment ctDNA. Patients with ERBB2 amplification in both tumor and ctDNA had longer PFS; median 16.4 (n = 14, 95% CI 13.0–NA) versus 6.2 months (n = 12, 95% CI 5.9–NA) in those who did not (p = 0.013). Interpretation Pembrolizumab can be safely combined with trastuzumab and chemotherapy and has promising activity in HER2-positive mEG cancer irrespective of PD-L1 status. Plasma-based ctDNA should be explored in future randomized studies as a predictive biomarker. A randomized phase 3 clinical trial assessing the efficacy and safety of pembrolizumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive mEG cancer is currently underway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30169-8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 362

Metadata

Authors
Janjigian, Y. Y., Maron, S. B., Chatila, W. K., Millang, B., Chavan, S. S., Alterman, C., Chou, J. F., Segal, M. F., Simmons, M. Z., Momtaz, P., Shcherba, M., Ku, G. Y., Zervoudakis, A., Won, E. S., Kelsen, D. P., Ilson, D. H., Nagy, R. J., Lanman, R. B., Ptashkin, R. N., Donoghue, M. T. A., Capanu, M., Taylor, B. S., Solit, D. B., Schultz, N., & Hechtman, J. F.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-06
Volume
21
Issue
6
Pages
821-831
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3024911178
Cited by
362
References
9
FWCI
31.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30169-8
The paper
Janjigian, Y. Y., Maron, S. B., Chatila, W. K., Millang, B., Chavan, S. S., Alterman, C., Chou, J. F., Segal, M. F., Simmons, M. Z., Momtaz, P., Shcherba, M., Ku, G. Y., Zervoudakis, A., Won, E. S., Kelsen, D. P., Ilson, D. H., Nagy, R. J., Lanman, R. B., Ptashkin, R. N., . . . Hechtman, J. F. (2020). First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30169-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.